Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Semaglutide stories

Nov 9, 2026

FDA requires GLP-1 drugmakers to add warning for rare eye condition

The FDA ordered makers of all GLP-1 medications, including Ozempic and Zepbound, to add label warnings about nonarteritic anterior ischemic optic neuropathy (NAION), a rare condition that can cause permanent vision loss.

Nov 9, 2026·8 sources
00
Nov 8, 2026

Semaglutide improves cardiac structure and hemodynamics in heart failure with preserved ejection fraction

Two placebo-controlled trials presented at the 2026 AHA Scientific Sessions found semaglutide significantly improved cardiac structure, function, and pulmonary artery wedge pressure in patients with heart failure with preserved ejection fraction and obesity.

Nov 8, 2026·2 sources
00
Sep 30, 2026

Regeneron weight-loss drug halves muscle loss when combined with semaglutide

An experimental weight-loss drug from Regeneron reduced muscle mass loss by 50% when used in combination with Novo Nordisk's semaglutide, compared to semaglutide alone, according to trial results presented at a medical meeting.

Sep 30, 2026·2 sources
00
Sep 9, 2026

Semaglutide linked to 40% reduction in asthma attacks in large real-world study

A large observational study found semaglutide (Ozempic/Wegovy) was associated with nearly 40% fewer asthma attacks and about 20% fewer COPD flare-ups compared to other treatments.

Sep 9, 2026·2 sources
00
Sep 7, 2026

Novo Nordisk's Wegovy helps 40% of young children lose enough weight to no longer be obese in trial

In a late-stage trial, 40.4% of children aged 6 to under 12 treated with semaglutide (Wegovy's active ingredient) were no longer obese after treatment, compared to the control group.

Sep 7, 2026·2 sources
00
Jul 14, 2026

Semaglutide may slow biological aging in adults with HIV

Researchers found that semaglutide, the active ingredient in Ozempic and Wegovy, slowed biological aging markers in adults with HIV, marking the first clinical evidence that the drug may influence human aging beyond its metabolic effects.

Jul 14, 2026·1 source
00
May 2, 2026

GLP-1 Drug Semaglutide Reduces Heavy Drinking Days by 50% in Alcohol Use Disorder Trial

A clinical trial of 108 adults with obesity and alcohol use disorder found that once-weekly semaglutide injections reduced heavy drinking days in the past 30 days by an average of roughly 12 days, representing a 50% reduction compared to placebo.

May 2, 2026·1 source
00
May 1, 2026

FDA Moves to Remove GLP-1 Weight Loss Drugs from Compounding List

FDA announced plans to exclude semaglutide, tirzepatide, and liraglutide from its 503B compounding list, citing no shortage of GLP-1 drugs from Novo Nordisk and Eli Lilly.

May 1, 2026·1 source
00
Apr 18, 2026

Weight Loss Medications Lead to Notable Muscle Loss Alongside Fat Loss

UNC School of Medicine study finds incretin-based medications including semaglutide and tirzepatide cause significant muscle loss in addition to fat reduction, raising concerns about long-term metabolic effects.

Apr 18, 2026·1 source
00
Apr 10, 2026

AI Analysis of 400,000 Reddit Posts Identifies Overlooked GLP-1 Drug Side Effects

University of Pennsylvania researchers used AI to analyze over 400,000 Reddit posts to identify patient-reported symptoms associated with semaglutide and tirzepatide that may not be captured in clinical trials.

Apr 10, 2026·1 source
00

Top claims

  • ▪The FDA required all GLP-1 drug manufacturers to add a nonarteritic anterior ischemic optic neuropathy safety warning to drug labels
  • ▪Cases of nonarteritic anterior ischemic optic neuropathy have been reported across all currently marketed GLP-1 medications, including semaglutide and tirzepatide products
  • ▪Nonarteritic anterior ischemic optic neuropathy is a rare eye condition caused by reduced blood flow to the optic nerve that can lead to sudden, permanent vision loss or blindness

Topics

Drug labeling & regulationDrug Policy, Pricing & ApprovalDrug safety & pharmacovigilanceGLP-1 medicationsEli LillyDrug safetyPost-market surveillanceGLP-1 receptor agonistsFDA regulationZepboundNovo NordiskGLP-1 drug side effectsMedical imagingClinical trialsCardiovascular diseasesRandomized controlled trialObesityHeart healthObesity treatmentMetabolic healthGLP-1 drugsWeight managementReal world evidenceDrug Approval and Clinical TrialsSupplementationEvidence based supplementationWeight loss medications & GLP-1 drugsLifestyle, Wellness and NutritionRespiratory healthGLP-1 / Weight-Loss MedicationsPharmaChildhood obesityLongevity & agingInfectious Disease and OutbreaksAddiction and Harm ReductionDrug supplement interactionsAlcohol Use DisorderMental Health & WellbeingAddiction & recoveryHealthcare PolicyEnvironmental and Occupational HealthEnvironmental exposures & toxicologyDiet & nutritionHealthAI data analysisAI safety & social impactAI privacy & surveillanceAI research & benchmarksAI

Related entities

OzempicTirzepatideWegovyGeriatric medicineObesityLiraglutide